Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 335

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 335
---
 to purchase one share of common stock at a price of $11.50 per share.

Simultaneously with the closing of the initial public offering pursuant to warrant purchase agreements, Iris completed the private sale of an aggregate of 5,013,333 private placement warrants to the Sponsor and Cantor Fitzgerald & Co. at a purchase price of $1.50 per private placement warrant. The sale of the private placement warrants generated gross proceeds to Iris of $7,520,000.

On June 1, 2022, Tribe Capital Markets LLC (“Tribe Capital”) withdrew as a member of the Sponsor. In connection with the withdrawal of Tribe Capital as a member of the Sponsor: (1) on July 26, 2022, the following actions occurred: (i) Arjun Sethi resigned in his capacity as Chairman and Chief Executive Officer, (ii) Henry Ward resigned from his role as an independent director, (iii) Omar Chohan resigned from his role as Chief Financial Officer of Iris, and (iv) Ted Maidenberg resigned from his role as Secretary; and (2) on July 27, 2022, the following actions occurred (i) the Sponsor changed its name from Tribe Arrow Holdings I LLC, to Iris Acquisition Holdings LLC, and (ii) Iris’s strategy to identify a target business was revised so that there is no restriction in the geographic location or business of targets we can pursue. However, with the change of management, we intended to prioritize (i) emerging markets followed by the United States and rest of Asia (excluding China and Hong Kong), and (ii) technology-led companies focused on essential sectors. The director and officer departures were not the result of any disagreement between us and such individuals on any matter relating to our operations, policies, or practices.

Effective July 26, 2022, the Iris Board appointed: (i) Sumit Mehta to serve as Iris’s Chief Executive Officer, (ii) Lisha Parmar to serve as Iris’s Chief Financial Officer, and (iii) Omkar Halady to serve as the Vice President of Iris. Also, Rohit Nanani was elevated from member to Chairman of the Iris Board.

On August 30, 2022, the Iris Board appointed Manish Shah to serve as a director until Iris’s next annual meeting of stockholders. On November 14, 2022, Duriya Farooqui resigned from the Iris Board, effective December 15, 2022.

On December 20, 202